These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35278846)

  • 1. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS.
    Li J; Chikermane SG; Earla JR; Hutton GJ; Aparasu RR
    Mult Scler Relat Disord; 2022 Apr; 60():103703. PubMed ID: 35278846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records.
    Earla JR; Hutton GJ; Thornton JD; Aparasu RR
    Mult Scler Relat Disord; 2020 Oct; 45():102334. PubMed ID: 32629400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribing of disease modifying agents in older adults with multiple sclerosis.
    Talwar A; Earla JR; Hutton GJ; Aparasu RR
    Mult Scler Relat Disord; 2022 Jan; 57():103308. PubMed ID: 35158421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis.
    Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
    Explor Res Clin Soc Pharm; 2021 Jun; 2():100021. PubMed ID: 35481133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis.
    Earla JR; Hutton GJ; Thornton DJ; Chen H; Johnson ML; Aparasu RR
    Pharmacotherapy; 2021 May; 41(5):440-450. PubMed ID: 33641232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis.
    Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
    Patient Prefer Adherence; 2020; 14():2187-2199. PubMed ID: 33177813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.
    Earla JR; Li J; Hutton GJ; Johnson ML; Aparasu RR
    Pharmacotherapy; 2023 Jun; 43(6):473-484. PubMed ID: 37157135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
    Earla JR; Li J; Hutton GJ; Bentley JP; Aparasu RR
    Mult Scler Relat Disord; 2024 May; 85():105539. PubMed ID: 38574721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from injectable to other Disease Modifying Therapies may improve sexual dysfunction in people with Multiple Sclerosis.
    Ala S; Amirkafi A; Kohandel K; Shahmohammadi S; Sahraian MA
    BMC Neurol; 2024 Jul; 24(1):255. PubMed ID: 39048953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
    Desai RJ; Mahesri M; Gagne JJ; Hurley E; Tong A; Chitnis T; Minden S; Spettell CM; Matlin OS; Shrank WH; Choudhry NK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):113-121. PubMed ID: 30589630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data.
    Earla JR; Paranjpe R; Kachru N; Hutton GJ; Aparasu RR
    Res Social Adm Pharm; 2020 Dec; 16(12):1670-1676. PubMed ID: 32171597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
    Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
    CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.
    Duchesneau ED; Kinlaw AC; Jonsson Funk M; Pate V; Lund JL
    Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):481-487. PubMed ID: 35088492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
    Cascione M; Tenenbaum N; Wendt J; Meng X; Schofield L; Cree BAC;
    Mult Scler Relat Disord; 2018 Oct; 25():50-56. PubMed ID: 30036854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
    Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of dimethyl fumarate as first line therapy in MS patients - one center real life observation study.
    Sałacińska D; Pogoda A; Żółkiewicz J; Stępień A
    Pol Merkur Lekarski; 2019 Dec; 47(282):221-225. PubMed ID: 31945023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.